

(BMSIC/DRUGS/15-05)

S.N.	Technical Eligibility Criteria as per NIT	<p>Name of Bidder : M/s Biogenetic Drugs Pvt. Ltd. Corporate Address : 66, Mathur Vaish Nagar Tonk Road, Jaipur- 302011, Rajasthan Manufacturing Unit Address : Village Jharmazri, Baddi, District Solan - HP -174103 "Chart has been prepared on the basis of number of downloaded Pg. received (i.e.- 1-166) "</p>
1	Constitution of the Bidding Company/Firm such as Memorandum of Association and Article of Association with complete address. As per Clause 3(c).	<p>Copy of certificate of incorporation No. 17-018909 of 2003-2014 in the name of Biogenetic Drugs Pvt. Ltd. issued by Registrar of companies , Rajasthan, Jaipur on dated 23rd January 2004 . (Pg. no. 125) Copy of MOA submitted. (Pg. no. 106-124) Bidder details- Name, Address, Telephone No, E-Mail and Fax No of Parters of the company as per annexure-V submitted. (Pg No. 137)</p>
2	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3 (e) of the NIT.	Self Attested copy of Power of Attorney submitted by Chairman & Managing Director of the Bidder firm, Mr. Mukut Bihari Goyal appoint & authorize Mr. Vibhor Goyal as Authorised signatory to file the Tender of BMSICL. (Pg No. 132)
3	List of item Quoted in prescribed format as Annexure III as per Clause 3 (c)	<p>List of quoted item : Products NIT S.No- 6 Albendazole Oral Suspension IP 200mg/5ml, 7 Albendazole Tablets IP 400mg, 23 Antacid Tablets, Tablet containing Dried Aluminium Hydroxide Gel- 250, Mag Hydroxide-250mg, Activated Dimethicon 50mg, 29 Azithromycin Oral Suspension IP 200mg/5ml, 36 Calcium Tablets, Each tablets contains : Calcium carbonate equivalent to 500mg elemental calcium and Vit. D3-250 I.U., 58 Cetrizine Hydrochloride Tablets IP 10mg, 59 Cetrizine Syrup IP 5mg/5ml, 65 Ciprofloxacin Hydrochloride Tablets IP 250mg, 81 Dicyclomine HCL and Paracetamol, Each tab. contains : Dicyclomine HCL 20mg & Paracetamol 325mg, 87 Doxycycline Capsules IP 100mg, 106 Iron and Folic Acid Syrup IP , 118 Levocetrizine Dihydrochloride Syrup, Each 5ml contains : Levocetrizine Dihydrochloride IP 2.5mg, 148 Ofloxacin & Ornidazole Suspension, 151 Ofloxacin Oral Suspension IP 50mg/5ml , 158 Paracetamol Paediatric Oral Suspension 50mg/ml, 159 Paracetamol Syrup IP 125mg/5ml, 179 Ranitidine Tablets IP 150mg (Total items 17)</p>
4	<ul style="list-style-type: none"> • Minimum three years old valid manufacturing licence of the product quoted with latest license renewal certificate. As per clause 3(f). • Approved product list as per the license issued for quoted drugs for minimum three years. As per clause 3(f). • Manufacturing License along with approved product list must be valid till the last date of the submission of tender. As per clause 3(f). <p>Bidders shall submit self attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it. As per Clause 3(f)</p>	<p>Copy of Manufacturing Licence in Form-25 & 28 having Mfg no. MNB/05-150 dated 28.06.2005 and MB/05-151 dated 28.06.2005 issued by Drug Controlling cum licensing authority , Shimla , H.P. in the name of M/s Biogenetic Drugs Pvt. Ltd. , Vill - Jharmazri, Baddi, Distt- Solan submitted. (Pg. no. 70-71) Copy of Renewal in Form -26 having Mfg no. MNB/05/150 & MB/05/151 issued on 28.06.2005, renewed up to 27.06.2020 submitted. (Pg. No. 73) Approved products list:- Products NIT S.No- 6. Albendazole Oral Suspension IP 200mg/5ml (approval dated not clear, pg. no.56 in which under headings of brand name ALBENDAZOLE ORAL SUSPENSION U.S.P is mentioned) , 7. Albendazole Tablets IP 400mg (approval dated on 28.06.2005, pg. no. 52, sl.no. 01), 23. Antacid Tablets, Tablet containing Dried Aluminium Hydroxide Gel- 250, Mag Hydroxide-250mg, Activated Dimethicon 50mg (approval date not clear, pg. no. 57, sl.no. 1) (Tablets section) , 29. Azithromycin Oral Suspension IP 200mg/5ml (approval date not clear, pg. no. 46, sl.no. 7)-Pack size not specified whereas NIT Specification is 15ml. 36. Calcium Tablets, Each tablets contains : Calcium carbonate equivalent to 500mg elemental calcium and Vit. D3-250 I.U. (approval dated- not clear but prior to 27.06.2010, refer pg. no. 54, sl.no. 4) , 58. Cetrizine Hydrochloride Tablets IP 10mg (approval dated on 06.07.2015, pg. no. 67, sl.no. 09, three years not complies as per clause 3(f)) 59. Cetrizine Syrup IP 5mg/5ml (approval dated on 18.10.2010, pg. no. 55, sl.no. 01), -Pack size is not specified 65. Ciprofloxacin Hydrochloride Tablets IP 250mg (approval dated on 28.06.2005, pg. no. 52, sl.no. 05), 81. Dicyclomine HCL and Paracetamol, Each tab. contains : Dicyclomine HCL 20mg & Paracetamol 325mg (approval dated on 06.09.2010, pg. no. 50, sl.no. 10, in which Composition not matches as per NIT specification), 87. Doxycycline Capsules IP 100mg (approval dated on 07.08.2006, pg. no. 47, sl.no. 04 wherein approval is given in Form 28 A), 106. Iron and Folic Acid Syrup IP- Each 5ml contains Ferrous sulphate equivalent to 100mg of elemental ferrous iron & 0.5 mg of Folic acid (To be labelled as per schedule V) (Pack size not specified 200ml as per NIT & approval date not clear, pg. no. 57, sl.no. 1 (Liquid section) , 118. Levocetrizine Dihydrochloride Syrup ,Each 5ml contains : Levocetrizine Dihydrochloride IP 2.5mg (Pack size not specified 30ml as per NIT & approval dated on 24.10.2007, pg. no. 51, sl.no. 01 (In liquid section), 148. Ofloxacin & Ornidazole Suspension, Each 5ml contains : Ofloxacin IP 50mg and Ornidazole IP 125mg (Pack size not specified 30ml as per NIT & approval dated on 06.09.2010, pg. no. 48, sl.no. 01), 151. Ofloxacin Oral Suspension IP 50mg/5ml (Pack size not specified 30ml as per NIT & approval dated on 06.09.2010, pg. no. 48, sl.no. 02), 158. Paracetamol Paediatric Oral Suspension 50mg/ml ((Pack size not specified 15ml as per NIT & approval dated on 27.12.2006, pg. no. 49, sl.no. 6, 159. Paracetamol Syrup IP 125mg/5ml (Pack size not specified 60ml as per NIT approval dated on 27.12.2006, pg. no. 49, sl.no. 05), 179. Ranitidine Tablets IP 150mg (approval dated on 28.06.2005, pg. no. 52, sl.no. 10) (Total items 17)</p>
5	In case of Importer, the bidder (importer) firm must have minimum three years old valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.As per Clause 3(g)	NA
6	Self attested copies of Market standing certificate (in India) of minimum three years, issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. As per Clause 3(h)	Self attested copies of Market standing certificates submitted for quoted product issued by State Drug controller, controlling cum licensing authority, Baddi, Solan, H.P. vide letter no-nil dt 31.08.2015, wherein 3 years of Market standing is mentioned. (Pg. No. 96-102)

7	Self attested copy of Non Conviction Certificate (NCC), issued by the concerned Licensing Authority from Drug Control Administration of the state for last three years. It should be not more than one year old. As per Clause 3(i).	1)Self attested copy of Non Conviction Certificate (NCC) issued by State Drug controller, controlling cum licensing authority, Baddi, Solan, H.P. vide letter no- 339/05 dt 31.08.2015 stated as" Said firm and its quoted products has not been convicted during the last three years by any court of law in the state. In which description of NIT sl.no. 81 & NIT sl.no. 179 not mentioned. (Pg. No. 88-92) 2) Self attested copy of NCC submitted issued by State Drug controller, controlling cum licensing authority, Baddi, Solan, H.P. on dated 19.02.2014, wherein description of NIT sl.no. 179 is mentioned, which is more than one year old as per Clause 3(i). (pg. no. 86-87) 3)Self attested copy of NCC submitted issued by State Drug controller, controlling cum licensing authority, Baddi, Solan, H.P. on dated 16.02.2012, wherein description of NIT sl.no. 81 is mentioned, which is more than one year old as per Clause 3(i). (Pg. no. 84-85)
8	Self attested copies of WHO-GMP/GMP as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority / Drugs Control Department. The GMP certificate must not be older than one year form the last date of submission of tender. As per clause 3(j).	Self attested copies of GMP as per Revised Schedule 'M' of D & C Rules 1945 in respect of category of Tablets , Capsules, Liquid Oral, Oral Powder issued by State Drug controller, controlling cum licensing authority, Baddi, Solan, H.P. vide letter no.- Nil dt 07.07.2015. Which is valid for 02 year from date of issue submitted. (Pg. No. 104)
9	Self attested copies of Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority form Drugs Control Department highlighting the quoted product section. As per Clause 3(k).	Self attested copies of Annual Production Capacity Certificate (section wise) issued by State Drug controller, controlling cum licensing authority, Baddi, Solan, H.P. vide letter no. 156/05 dt. 30.06.2014 submitted. Wherein Tablets - 448 Million Tablets 50 days , Capsule 62 Million Capsules 50 days and Oral Liquid 30 Million Bottles 50 days is mentioned. (Pg no. 81 & 82)
10	An affidavit sworn before first class magistrate/Notary stating that the firm & its quoted product is not black listed currently (as on the last date of submission of the tender) by Central Government/ Central Government Agencies/any state government/any of the state government agencies/any Drug Procurement Agencies or by BMSICL as per Annexure II (clause 3(n) of NIT).	Copy of affidavit sworn before Notary by authorised signatory of the bidder firm stating that the firm & its quoted product is not black listed currently (as on the last date of submission of the tender) by Central Government/ Central Government Agencies/any state government/any of the state government agencies/any Drug Procurement Agencies or by BMSICL as per Annexure-II submitted. (Pg. 93-94)
11	EMD details (DD number/BG number and date with issuing bank) as per Clause 3(b).	Rs. 300000/-, BG No. 36920IGL0004315, UBI, Pg. 03
12	Tender Fee Rs 10,000/- in form of DD as per Clause 3(a).	Rs. 10000/-, DD No. 303576, Union Bank of India, Pg. 06
13	Self attested copies of the Audited Annual Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 crores for any three of the last four consecutive financial years. (Auditor/ C.A. Certificate of turnover will not be accepted). As per Clause 3(l)	F.Y. 2013-14 Pg. 21-22 Rs. 52.74 Cr. F.Y. 2013-14 Annual Turnover not visiable Pg. 33-34 F.Y. 2014-15 Provisional Balance sheet . Pg. 36-38
14	Self attested copy of Income Tax Return for any three of last four consecutive Assessment years. As per Clause 3(m).	A.Y. 2012-13 Pg. 40 A.Y. 2013-14 Pg. 41 A.Y. 2014-15 Pg. 42
15	Self attested copy of PAN Card of the Bidder Company. As per Clause 3(p)	Pan No. AACCB3897K, Pg. 44
16	Self attested copy of Certificate of valid Sales tax/VAT registration of the bidder company. As per Clause 3(q)	TIN No. 02030100232, Pg. 13
17	Affidavit declaration regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure IV (Clause 5(k) of NIT).	Copy of an affidavit sworn before Notary by authorized person on dt. 01.09.2015 stating acceptance of tender conditions as per annexure-IV. Submitted.(Pg. No. 08-09)

The facts in clause No-1 to 10 and 17 of the provided sheet has been compiled with due diligence and care, on the basis of document provided by BMSICL, in compliance of letter No 515(15) Dt-21.08.2015 of Health Department, Govt of Bihar and letter no BMSIC/40010/2-2014/1678 Dt 18.09.2015 of GM (Supply Chain), BMSICL, Patna. In spite, some inadvertent discrepancies could have been crept in. Humble request to all concerned to bring to notice in due time, if any discrepancies is observed, for rectification.

AS

Sushash

The facts in pages mentioned against the clause No-1 to 10 and 17 of this chart has been evaluated & verified